32 results about "Antibody receptor" patented technology

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.

A fusion protein for delivery of a wide variety of agents to a cell via antibody-receptor-mediated endocytosis comprises a first segment and a second segment: the first segment comprising a variable region of an antibody that recognizes an antigen on the surface of a cell that after binding to the variable region of the antibody undergoes antibody-receptor-mediated endocytosis, and, optionally, further comprises at least one domain of a constant region of an antibody; and the second segment comprising a protein domain selected from the group consisting of avidin, an avidin mutein, a chemically modified avidin derivative, streptavidin, a streptavidin mutein, and a chemically modified streptavidin derivative. Typically, the antigen is a protein. Typically, the protein antigen on the surface of the cell is a receptor such as a transferrin receptor-or an insulin receptor. The invention also includes an antibody construct incorporating the fusion protein that is either a heavy chain or a light chain together with a complementary light chain or heavy chain to form an intact antibody molecule. The invention further includes targeting methods and screening methods.

The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions, and use of the antibodies and antibody composition for treatment of cancers. The antibody composition comprises at least three recombinant antibodies that bind distinct epitopes of HER2. Two of the antibodies bind to HER2 on the surface of a cell such that they generate a cross-linked antibody-receptor lattice on the cell surface and thereby result in HER2 receptor internalization. The third antibody in the composition binds HER2 such that it blocks heterodimerization between HER2 and HER3.

This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer antigens, autoantigens, or pathogens.

The invention relates to a homogeneous immunoassay method, in which at least two detection regions are used, in one detection region, it is determined whether a first composite formed by a donor-antibody to be detected-receptor exists or not, in the other detection region, it is determined whether a second composite formed by a donor-antigen to be detected-receptor exists or not. Wherein the donorcan generate singlet oxygen in an excited state, and the receptor can react with the singlet oxygen to generate a detectable signal. The method solves the problems of HOOK effect of a high-concentration sample and low detection sensitivity of a low-concentration sample in antigen-antibody one-step detection. Meanwhile, the method also solves the problem that whether a positive result is antibodypositive or antigen positive cannot be distinguished during antigen-antibody combined detection. The method provided by the invention is especially suitable for combined detection of HIV antigen and antibody.

The invention relates to the field of biological detection and discloses a detection device and a detection method of a large class of beta-agonists drugs by applying an immune chromatography technology. According to the invention, an antibody/receptor which is reacted with a large class of the beta-agonists drugs is used for preparing an immune chromatography test strip to realize the simultaneous detection of a large class of the beta-agonists drugs. Compared with the prior art, the detection on a large class of the beta-agonists drugs for one time can be realized, the detection cost is low and the method is convenient and fast.

The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

An engineered immune cell that does not express a T cell receptor (TCR) and comprises a CD3 antibody receptor complex. The invention also relates to a pharmaceutical composition containing the modified immune cell and a bispecific antibody, and an application of the pharmaceutical composition in preparation of medicines.

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.

Chimeric autoantibody receptors (CAARs) can include separate signaling and recognition constructs that are able to bind ligands that target autoantigens made of conventional amino acids, non-conventional amino acids, carbohydrates, or nucleic acids. Additionally, the present disclosure describes cells modified to express such constructs and the use of such constructs and/or cells in the treatment of autoimmune disease.

The present disclosure provides a chimeric autoantibody receptor (CAAR) that is specific for an autoantibody-based B cell receptor (BCR), wherein the autoantibody is specific for nAChR. The disclosure also provides compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising the polynucleotides encoding the CAAR, engineered cells comprising the CAAR, and methods of using the same.

The present disclosure provides a chimeric anti-drug antibody receptor (CADAR) having specificity for an anti-drug antibody based B cell receptor (BCR), wherein the anti-drug antibody is induced by a therapeutic anti-TNF-alpha monoclonal antibody. The disclosure also provides compositions comprising the CADAR, polynucleotides encoding the CADAR, vectors comprising the polynucleotides encoding the CADAR, engineered cells comprising the CADAR, and methods of using the same.

The invention provides a targeting antibody prodrug which is composed of a part A, a part B and a part C. The part A is a protein with targeting performance, the part C is an antibody/antibody receptor fusion protein with a therapeutic effect, the part A is connected with the part C through the part B, the part B is connected with the part C through the part C, and the part A with the targeting protein is connected to the antigen binding region of the part C antibody.

The invention discloses a model cell capable of expressing anti-human DSG3scFv on the cell surface and a construction method of the model cell, an artificially designed membrane type anti-DSG3 single-chain antibody is expressed on the surface of the model cell, the model cell can be combined with a T cell expressing an anti-DSG3 autoantibody receptor (CAAR), namely, a CAAR-T cell, the model cell is used for identifying a killing evaluation system of the chimeric autoantibody receptor (CAAR) CAAR-T cell, and the model cell can be used for identifying the killing evaluation system of the CAAR-T cell. And a simple, convenient and easily available experimental tool is provided for the application of the CAAR-T cells.